ResultsIQ

ResultsIQ › Latest results › Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited Q3 FY26 results deck summary

NSE: DCAL · BSE: 540701

Results deck of 4 Feb 2026, summarised by AI from the filing.

Q3 FY26 net revenue rose 5.5% YoY to ₹7,198 mn, but EBITDA margin fell to 15.7% and PAT was -₹129.7 mn.

Key takeaways

  1. Q3 revenue Net revenue ₹7,198 mn in Q3 FY26, up 5.5% YoY from ₹6,823 mn, on higher CDMO revenue.
  2. Segment mix CDMO Q3 revenue ₹6,297.4 mn (+6.7% YoY); Marketable Molecules ₹900.6 mn (-2.4% YoY).
  3. Growth driver 9M FY26 revenue up 4.3% YoY on higher Cholesterol and Vitamin D analogues revenue contribution.
  4. Margin risk CDMO margin fell to 16.9% in Q3 FY26 from 22.1% on lower late Phase III molecule contribution.

Original filing on BSE

Dishman Carbogen Amcis Limited Q1 FY27 results

As filed: Revenue ₹678 cr (−4% year on year), EBITDA ₹60.1 cr (−57% year on year), PAT −₹57.9 cr (−300% year on year), EBITDA margin 8.9% (−1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹851 cr (+19% year on year), EBITDA ₹163 cr (+7% year on year), PAT ₹21.7 cr (−49% year on year), EBITDA margin 19.1% (−223 bps). Score 44 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it. EBITDA margin fell 223 bps year on year. Other income 36% of PBT. Tax rate 53%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −9.7% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹720 cr (+6% year on year), EBITDA ₹113 cr (−19% year on year), PAT −₹13.0 cr (−300% year on year), EBITDA margin 15.7% (−481 bps). Score 20 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it. EBITDA margin fell 481 bps year on year. Profit fell 120% from last quarter. Share price after the results: −28.1% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹653 cr (−17% year on year), EBITDA ₹149 cr (+1% year on year), PAT ₹65.0 cr (+97% year on year), EBITDA margin 22.8% (+419 bps). Score 16 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA growth was below it. EBITDA margin rose 419 bps year on year. Other income 26% of PBT. Tax rate -113%. Consolidated profit +97% but standalone -200%. Revenue fell 8% from last quarter. Share price after the results: −23.2% in 30 days (Nifty 500: +0.3%).
  • Q1 FY26: Revenue ₹708 cr (+35% year on year), EBITDA ₹141 cr (+300% year on year), PAT ₹23.0 cr, EBITDA margin 19.9% (+1,000 bps). Score 69 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Other income 64% of PBT. Tax rate 41%. Profit fell 47% from last quarter. Share price after the results: +10.2% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹716 cr (+9% year on year), EBITDA ₹153 cr (+143% year on year), PAT ₹43.0 cr, EBITDA margin 21.4% (+1,000 bps). Score 58 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it. EBITDA margin rose 1000 bps year on year. Other income 29% of PBT. Tax rate -57%. Share price after the results: +10.8% in 30 days (Nifty 500: +1.4%).
  • Q3 FY25: Revenue ₹682 cr (+5% year on year), EBITDA ₹140 cr (+241% year on year), PAT ₹5.0 cr, EBITDA margin 20.5% (+1,000 bps). Score 66 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA growth was well above it. EBITDA margin rose 1000 bps year on year. Tax rate 85%. Revenue fell 14% from last quarter.
  • Q2 FY25: Revenue ₹789 cr (+34% year on year), EBITDA ₹147 cr (+141% year on year), PAT ₹33.0 cr, EBITDA margin 18.6% (+824 bps). Score 95 of 100, Above trend. EBITDA margin rose 824 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Dishman Carbogen Amcis Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.